Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from …
JCH Yang, YL Wu, M Schuler, M Sebastian… - The lancet …, 2015 - thelancet.com
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma …
JCH Yang, MH Schuler, N Yamamoto, KJ O'Byrne… - 2012 - ascopubs.org
LBA7500 Background: Afatinib (A) is a selective, orally bioavailable, irreversible ErbB family
blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the …
blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the …
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of …
T Kato, H Yoshioka, I Okamoto, A Yokoyama… - Cancer …, 2015 - Wiley Online Library
In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised …
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer… - The Lancet …, 2016 - thelancet.com
Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
JCH Yang, JY Shih, WC Su, TC Hsia, CM Tsai… - The lancet …, 2012 - thelancet.com
Background Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-
small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of …
small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The lancet …, 2015 - thelancet.com
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR …
8016 Background: A is an oral, irreversible, ErbB Family Blocker, blocking signaling from
EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in …
EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in …
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review
J Köhler, M Schuler - Onkologie, 2013 - karger.com
Non-small cell lung cancer (NSCLC) consists of several histomorphologically defined
phenotypes that display an enormous genetic variability. In recent years, epidermal growth …
phenotypes that display an enormous genetic variability. In recent years, epidermal growth …
[HTML][HTML] Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX …
Background Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …
相关搜索
- lux lung egfr mutations
- lux lung afatinib for patients
- lux lung subgroup analysis
- egfr mutations subgroup analysis
- lung adenocarcinoma efficacy of afatinib
- lung adenocarcinoma receptor mutations
- egfr mutations japanese patients
- lux lung dose adjustment
- receptor mutations afatinib for patients
- lux lung safety and efficacy
- lux lung growth factor
- lung adenocarcinoma afatinib for patients
- lux lung efficacy of afatinib
- lux lung receptor mutations
- lux lung gefitinib in patients
- lux lung japanese patients